Home / Research library / Tesofensine Capsules
Tesofensine Capsules: molecular data, studies & sources
Tesofensine Capsules is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.
Compiled by PeptideTech Editors · Sources checked · Selected bibliography, not a systematic review
Molecular formula, weight & structure
- Molecular formula (MF)
- C17H23Cl2NO
- Molecular weight (MW)
- 328.3 g/mol
- PubChem compound ID
- 11370864
- Record title
- Tesofensine
Values describe the selected PubChem molecular entity. Counterions, salt forms, hydration and sequence changes can alter the supplied material. Confirm the exact identity against the supplier specification.
Source: PubChem CID 11370864 · retrieved 2026-09-21
Chemical identifiers and source data
- IUPAC name
- (1R,2R,3S,5S)-3-(3,4-dichlorophenyl)-2-(ethoxymethyl)-8-methyl-8-azabicyclo[3.2.1]octane
- InChIKey
- VCVWXKKWDOJNIT-ZOMKSWQUSA-N
- SMILES
- CCOC[C@H]1[C@H]2CC[C@H](N2C)C[C@@H]1C3=CC(=C(C=C3)Cl)Cl
Identifiers
- PubChem CID
- 11370864
- CAS Registry Number
- 195875-84-4via ChemIDplus, EPA DSSTox, FDA GSRS
- FDA UNII
- BLH9UKX9V1
- ChEMBL ID
- CHEMBL3989690
- InChIKey
- VCVWXKKWDOJNIT-ZOMKSWQUSA-N
- Wikidata
- Q7705544
Other names and development codes: NS-2330
CAS numbers are published only from ChemIDplus, EPA DSSTox or the FDA Global Substance Registration System; UNII codes are confirmed in FDA GSRS by structure, sequence or exact name. Checked 2026-10-07.
Calculated molecular descriptors
| Monoisotopic (exact) mass | 327.1157 Da |
|---|---|
| Heavy atoms | 21 |
| Hydrogen-bond donors | 0 |
| Hydrogen-bond acceptors | 2 |
| Rotatable bonds | 4 |
| Topological polar surface area | 12.5 Ų |
| Calculated logP (Crippen) | 4.60 |
| Rings | 3 |
| Stereocenters | 4 |
| Formal charge | 0 |
Computed with RDKit from the published SMILES (Crippen logP, topological polar surface area). Calculated descriptors are not measured properties of a supplied batch.
US regulatory status & drug development
Drugs@FDA lists no NDA, BLA or ANDA with tesofensine as an active ingredient (names searched: TESOFENSINE, TESOFENSINE CITRATE; checked October 7, 2026). Research-labelled Tesofensine Capsules listings are not FDA-approved drugs.
An FDA approval covers a defined medicine, formulation and labelled use. It does not extend to research-labelled material sold under the same compound name. Identity basis: INN tesofensine and its citrate were searched.
Source: Drugs@FDA via openFDA (active-ingredient search for TESOFENSINE, TESOFENSINE CITRATE) · checked . openFDA data are not intended for clinical decisions.
Drug development record (ChEMBL)
Harmonized drug-development record from ChEMBL. The highest clinical stage is the furthest stage reached, as recorded by ChEMBL; it can lag regulatory approvals, and it is not an approval of a research-supplier product.
- ChEMBL ID
- CHEMBL3989690
- Modality
- Small molecule
- Highest clinical stage
- Phase 2
- Record name
- TESOFENSINE
Mechanism of action
- Monoamine transporter inhibitor · target: Monoamine transporter (SLC6A2)
Synonyms, codes and trade names
- Synonyms and development codes
- NS 2330 · NS-2330 · Tesofensine
Identity check: Identical standard InChIKey to the PubChem record. Source: ChEMBL CHEMBL3989690 (EMBL-EBI, CC BY-SA 3.0) · retrieved 2026-10-07
Registered clinical trials
Studies registered on ClinicalTrials.gov that list Tesofensine as an intervention. Studies that only measure the molecule as a biomarker, or use it only as a comparator or background arm for another drug, are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.
9 registered studies matched, 4 with results posted on ClinicalTrials.gov.
- By highest phase
- Phase 2 · 8Phase 1 · 1
- By registry status
- Completed · 9
| Study | Phase · status | Conditions | Sponsor · size |
|---|---|---|---|
| 48 Weeks, Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol in Subjects With Hypothalamic Injury-induced Obesity (HIO)NCT03845075 · start 2019-02-25 · primary completion 2020-10-16 | Phase 2CompletedResults posted 2024-02-13 | Hypothalamic Injury-induced Obesity (HIO) | Saniona21 participants |
| Study to Investigate the Pharmacokinetic ProfileNCT03286829 · start 2017-12-18 · primary completion 2018-02-06 | Phase 1CompletedResults posted 2020-05-14 | Healthy Male Subjects | Saniona60 participants |
| Co-administration of Tesofensine/Metoprolol in Subjects With Prader-Willi Syndrome (PWS)NCT03149445 · start 2017-03-30 · primary completion 2019-07-22 | Phase 2CompletedResults posted 2024-02-26 | Confirmed Genetic Diagnosis of Prader-Willi Syndrome | Saniona18 participants |
| Safety and Efficacy Study of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes MellitusNCT02737891 · start 2016-04 · primary completion 2017-01 | Phase 2CompletedResults posted 2020-05-14 | Type 2 Diabetes Mellitus | Saniona60 participants |
| Evaluation of Long Term Safety of Tesofensine in Patients With ObesityNCT00481104 · start 2007-05 · primary completion 2008-09 | Phase 2Completed | Obesity | NeuroSearch A/S140 participants |
| Effect of Tesofensine on Energy Balance in Humans.NCT00428415 · start 2007-03 · primary completion 2007-12 | Phase 1 / Phase 2Completed | Obesity | NeuroSearch A/S32 participants |
| Effect of Tesofensine on Weight Reduction in Patients With Obesity.NCT00394667 · start 2006-09 | Phase 2Completed | Obesity | NeuroSearch A/S200 participants |
| A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Study of NS 2330 (Tesofensine) (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor FluctuationsNCT00148512 · start 2003-03 · primary completion 2005-02 | Phase 2Completed | Parkinson Disease | Boehringer Ingelheim254 participants |
| An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's TypeNCT00153010 · start 2003-02 · primary completion 2005-03 | Phase 2Completed | Alzheimer Disease | Boehringer Ingelheim430 participants |
Registry check 2026-10-09 · Run this search on ClinicalTrials.gov
Human intervention studies
Selected studies in which participants received Tesofensine, with their indexed or reviewed study type. Check the original article for the formulation, population and controls. Studies that only measured the molecule, or used it as a comparator, are listed separately below and are not counted as intervention studies.
- Human study · PubMed trial index Compound given to participants
Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users.
Schoedel KA, Meier D, Chakraborty B et al. · Clinical pharmacology and therapeutics · 2010
PMID 20520602 · DOI: 10.1038/clpt.2010.67
- Human study · PubMed trial index Compound given to participants
Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial.
Astrup A, Madsbad S, Breum L et al. · Lancet (London, England) · 2008
PMID 18950853 · DOI: 10.1016/S0140-6736(08)61525-1 · Registration NCT00394667
- Human study · PubMed trial index Compound given to participants
[The effect of tesofensine on body weight and body composition in obese subjects--secondary publication].
Nielsen AL, Larsen TM, Madsbad S et al. · Ugeskrift for laeger · 2009
PMID 19824222
- Human study · PubMed trial index Compound given to participants
Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study.
Rascol O, Poewe W, Lees A et al. · Archives of neurology · 2008
PMID 18474731 · DOI: 10.1001/archneur.65.5.577 · Registration NCT00148512
- Human study · PubMed trial index Compound given to participants
A quantitative enterohepatic circulation model: development and evaluation with tesofensine and meloxicam.
Lehr T, Staab A, Tillmann C et al. · Clinical pharmacokinetics · 2009
PMID 19705923 · DOI: 10.2165/11313370-000000000-00000
Preclinical research, reviews & other publications
Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.
- Review · secondary evidence
Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity.
Bello NT, Zahner MR · Current opinion in investigational drugs (London, England : 2000) · 2009
PMID 19777399
- Preclinical / laboratory research
Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons.
Perez CI, Luis-Islas J, Lopez A et al. · PloS one · 2024
PMID 38656972 · DOI: 10.1371/journal.pone.0300544
Tesofensine Capsules supplier sources
Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.
Tesofensine Capsules for sale: compare prices, sizes and forms from every tracked supplier →
| Supplier | Recorded packages | Example source listing |
|---|---|---|
| Amino USAUSD | 500mcg×30 Capsules1 recorded offers | 500mcg×30 Capsules · $124.99Checked Nov 6, 2026Supplier listing, Tesofensine Capsules 500mcg×30 Capsules, Amino USA, opens in a new tab |
| Cenexa LabsUSD | 500mcg×60 Capsules1 recorded offers | 500mcg×60 Capsules · $136.99Checked Nov 6, 2026Supplier listing, Tesofensine Capsules 500mcg×60 Capsules, Cenexa Labs, opens in a new tab |
Reference sources & further reading
- PubChem compound record 11370864 — chemical identity and structure.
- ChEMBL drug record CHEMBL3989690 — development stage, mechanism and synonyms.
- FDA Global Substance Registration System: UNII BLH9UKX9V1 — substance identity, names and codes.
- Wikipedia: Tesofensine — Background encyclopedia; not a primary clinical source.
The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.
Search for additional research
These links run searches; their results have not been individually reviewed and can include unrelated compounds.
Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.
Related research profiles
ACE-031
Molecular identity needs further verification
3 selected publications · 2 human intervention studies · 4 registered trials
Adipotide
C111H206N36O28S2
2557.2 g/mol · PubChem CID 163360068
1 selected publication · 0 human intervention studies
AICAR
C9H14N4O5
258.23 g/mol · PubChem CID 17513
4 selected publications · 3 human intervention studies · 4 registered trials
Small molecule · highest stage: Phase 3
B7-33
Molecular identity needs further verification
4 selected publications · 0 human intervention studies
BAM15 Capsules
Molecular identity needs further verification
8 selected publications · 0 human intervention studies
Dermorphin
C40H50N8O10
802.9 g/mol · PubChem CID 5485199
1 selected publication · 1 human intervention study